Drug intelligence / Profile preview

zabopegdutide

Development stage: Unknown
Lead developer: D&D Pharmatech
Modality: Peptides
Administration: Subcutaneous

Overview

Zabopegdutide (DD-01) is an investigational, once-weekly pegylated peptide dual receptor agonist that targets the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. Developed by D&D Pharmatech, the molecule features a dominant 11:1 GLP-1-to-glucagon potency ratio and is specifically designed for liver-targeted action. It is primarily being developed for metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), with potential applications in type 2 diabetes and obesity. In clinical studies, zabopegdutide has demonstrated significant reductions in liver fat content and improvements in glycemic control and weight loss.

Other names: zabopegdutide

Targets

GLP1R (GLP-1R)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on zabopegdutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zabopegdutide.

Explore the full profile